Merck Serono, the biopharmaceutical division of pharmaceutical conglomerate Merck, has made an investment in the series A round for US-based reproductive health company Auxogyn through its corporate venturing fund, Merck Serono Ventures. The round closed on Thursday, with Auxogyn having raised $20m.

Merck was joined in the round by TPG Biotech, the life sciences investment division of investment firm TPG, as well as venture capital firm Kleiner Perkins Caufield & Byers (KPCB). 

Auxogyn’s lead product is Eeva, a non-invasive…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?